Fecal Microbiota Transplantation for Treatment of Acute Graft-versus-Host Disease

Roni Shouval; Mika Geva; Arnon Nagler; Ilan Youngster

doi:10.2991/chi.d.190316.002

<Previous Article In Issue

Next Article In Issue>

Volume 1, Issue 1, March 2019, Pages 28 - 35

Fecal Microbiota Transplantation for Treatment of Acute Graft-versus-Host Disease

Authors

Roni Shouval¹^{, 2}^{, *}, Mika Geva¹, Arnon Nagler¹, Ilan Youngster³

¹Hematology and Bone Marrow Transplantation Division, Chaim Sheba Medical Center, Tel-Hashomer, Sackler School of Medicine, Tel Aviv University, Ramat-Gan, Israel

²Dr. Pinchas Bornstein Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Ramat-Gan, Israel

³Pediatric Division and Microbiome Research Center, Assaf Harofeh Medical Center, affiliated with Tel Aviv University, Zerifin, Israel

Peer review is under the responsibility of IACH

^*Corresponding author. E-mail: shouval@gmail.com

Corresponding Author

Roni Shouval

Received 12 February 2019, Accepted 4 March 2019, Available Online 18 April 2019.

DOI: 10.2991/chi.d.190316.002 How to use a DOI?
Keywords: Hematopoietic stem cell transplantation; Graft-versus-host disease; Microbiome; Fecal microbiota transplantation
Abstract: The growing understanding of the bidirectional relationship between the gastrointestinal (GI) microbiome and the immune system has opened up new avenues for treatment of graft-versus-host disease (GVHD). Fecal microbiota transplantation (FMT) is the transfer of stool from a donor to a recipient who harbors a perturbed GI microbiome resulting in disease. We review the rationale for performing FMT for the treatment of acute GVHD, and summarize data on the safety and efficacy of the procedure among allogeneic hematopoietic stem cell transplantation (HSCT) recipients. Overall, FMT is a promising strategy in treating and preventing HSCT-related complications. However, caution should be exerted as HSCT recipients are highly immunosuppressed and unanticipated infectious adverse events may appear with the increasing application of FMT.
Open Access: This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

<Previous Article In Issue

Next Article In Issue>

Journal: Clinical Hematology International
Volume-Issue: 1 - 1
Pages: 28 - 35
Publication Date: 2019/04/18
ISSN (Online): 2590-0048
DOI: 10.2991/chi.d.190316.002 How to use a DOI?
Open Access: This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

ris enw bib

TY  - JOUR
AU  - Roni Shouval
AU  - Mika Geva
AU  - Arnon Nagler
AU  - Ilan Youngster
PY  - 2019
DA  - 2019/04/18
TI  - Fecal Microbiota Transplantation for Treatment of Acute Graft-versus-Host Disease
JO  - Clinical Hematology International
SP  - 28
EP  - 35
VL  - 1
IS  - 1
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.d.190316.002
DO  - 10.2991/chi.d.190316.002
ID  - Shouval2019
ER  -

download .riscopy to clipboard